Human Reproduction, Vol 12, 2159-2161, Copyright © 1997 by Oxford University Press
F Parazzini, E Negri, C La Vecchia, S Moroni, S Franceschi and PG Crosignani
The relationship between the use of fertility drugs and the risk of ovarian
cancer was analysed using data from an Italian case-control study. The
study comprised 971 women below the age of 75 years with histologically
confirmed invasive epithelial ovarian cancer diagnosed within the year
before the interview. The controls were 2758 women admitted to the same
network of hospitals where the cases of ovarian cancer had been identified.
Five cases (0.5%) and 11 controls (0.4%) reported use of fertility drugs.
In comparison with women who had never used fertility drugs, the
multivariate odds ratio (OR) for women who had taken fertility drugs was
1.1 [95% confidence interval (CI) 0.4- 3.3]. The OR were 0.7 (95% CI
0.1-7.9) and 1.0 (95% CI 0.2-3.8) for women who had used fertility drugs
for <6 and > or =6 cycles respectively. Considering the 14 cases and
45 controls reporting difficulty in conception, the risk of ovarian cancer
was 0.5 (95% CI 0.1-3.6) for women who reported use of fertility drugs.
Considering nulliparous women only, the estimated OR of ovarian cancer for
any fertility drug use was 0.6 (95% CI 0.1-3.5). Although the present
results have limitations in terms of statistical power and available
information, they provide reassuring evidence of the absence of a strong
association between fertility drugs and subsequent risk of developing
epithelial ovarian cancer.
ARTICLES
Treatment for infertility and risk of invasive epithelial ovarian cancer
Istituto di Ricerche Farmacologiche Mario Negri, Universita degli Studi di Milano, Milan, Italy.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Jensen, H. Sharif, K. Frederiksen, and S. K. Kjaer Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study BMJ, February 5, 2009; 338(feb05_2): b249 - b249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jensen, H. Sharif, J. H. Olsen, and S. K. Kjaer Risk of Breast Cancer and Gynecologic Cancers in a Large Population of Nearly 50,000 Infertile Danish Women Am. J. Epidemiol., July 1, 2008; 168(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Klip, F. E. van Leeuwen, R. Schats, C.W. Burger, and for the OMEGA project group Risk of benign gynaecological diseases and hormonal disorders according to responsiveness to ovarian stimulation in IVF: a follow-up study of 8714 women Hum. Reprod., September 1, 2003; 18(9): 1951 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Parazzini, C. Pelucchi, E. Negri, S. Franceschi, R. Talamini, M. Montella, and C. La Vecchia Use of fertility drugs and risk of ovarian cancer Hum. Reprod., July 1, 2001; 16(7): 1372 - 1375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. La Vecchia, E. Negri, R. Talamini, E. Conti, M. Montella, and S. Franceschi Re: Multiple Births and Risk of Epithelial Ovarian Cancer J Natl Cancer Inst, February 21, 2001; 93(4): 319 - 319. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Keri, K. L. Lozada, F. W. Abdul-Karim, J. H. Nadeau, and J. H. Nilson Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition PNAS, January 4, 2000; 97(1): 383 - 387. [Abstract] [Full Text] [PDF]
|
|